Shineco, Inc., together with its subsidiaries, produces, distributes, and sells health and well-being focused plant-based products in China. It processes and distributes traditional Chinese herbal medicine products, as well as other pharmaceutical products directly to individual customers. The company also plants, processes, and distributes green and organic vegetables and fruits; and grows, cultivates, and sells yew trees that are used for the production of anti-cancer medication, as well as ornamental bonsai trees for purifying indoor air quality. In addition, it offers logistics services for agricultural products. Further, the company develops, manufactures, and distributes specialized fabrics, textiles, health supplements, and other byproducts derived from an indigenous Chinese plant Apocynum Venetum. The company sells its Chinese medicinal products and western medicines through wholesale customers; and its 13 Ankang retail pharmacies operating under the Sunsimiao Pharmacies name, as well as 66 pharmacies operated by third parties. It sells its decoction pieces on the Anhui Bozhou Chinese medicine transaction market to medical materials companies and Chinese patent medicine factories. The company sells its Luobuma textile products online through third party e-commerce websites, as well as through distributors under the Tenethealth brand; and yew trees and agricultural products primarily through its sales personnel, and group and institutional sales. The company was formerly known as Beijing Tenet Jove Technological Development Co., Ltd. and changed its name to Shineco, Inc. in June 2005. Shineco, Inc. was incorporated in 1997 and is based in Beijing, China.
IPO Year: 2016
Exchange: NASDAQ
Website: tianyiluobuma.com
SC 13G/A - SHINECO, INC. (0001300734) (Subject)
SC 13D - SHINECO, INC. (0001300734) (Subject)
SC 13G - SHINECO, INC. (0001300734) (Subject)
SC 13D - SHINECO, INC. (0001300734) (Subject)
8-K - SHINECO, INC. (0001300734) (Filer)
8-K - SHINECO, INC. (0001300734) (Filer)
EFFECT - SHINECO, INC. (0001300734) (Filer)
S-1/A - SHINECO, INC. (0001300734) (Filer)
S-1 - SHINECO, INC. (0001300734) (Filer)
RW - SHINECO, INC. (0001300734) (Filer)
10-Q - SHINECO, INC. (0001300734) (Filer)
S-3 - SHINECO, INC. (0001300734) (Filer)
8-K - SHINECO, INC. (0001300734) (Filer)
8-K - SHINECO, INC. (0001300734) (Filer)
NEW YORK, Aug. 9, 2024 /PRNewswire/ -- Future Fintech Group Inc. (NASDAQ: FTFT), (hereinafter referred to as "Future FinTech", "FTFT" or the "Company"), a comprehensive financial and digital technology service provider, today announced that its Board of Directors (the "Board") approved the appointment of Mr. Hu Li as Chief Executive Officer ("CEO"), President and a member of the Board of the Company, effective August 5, 2024. Mr. Li will be fully responsible for the operation and management of the Company, helping it to expand internationally, manage its investment and financi
BEIJING, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a provider of technologically advanced healthcare products and services, announced today that its Board of Directors has appointed Ms. Xiaohui Wang and Mr. Chi Keung Yan as executive officers of the Company in key leadership roles. Effective November 13, 2023, Shineco's Board of Directors appointed Ms. Xiaohui Wang as Executive President of the Company. From March 2000 to November 2013, Ms. Wang was the founder and Chairperson of Chongqing Wintus (New Star) Enterprises Group, where she was responsible for its corporate planning, supervision of the group's business in the Chongqing region,
BEIJING, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that the Company has appointed Professor Qiyin Sun as the Chief Medical Consultant. Professor Sun will lead the research and innovation of the Company's tumor treatment and provide technical consultation in early tumor screening and tumor radiotherapy to support the commercialization of digital tumor diagnosis and treatment. Prior to serving as the chief medical consultant at Shineco, Professor Sun was a director at Beijing Nuclear Medicine Equipment Engineering Technology R
3 - SHINECO, INC. (0001300734) (Issuer)
3 - SHINECO, INC. (0001300734) (Issuer)
3 - SHINECO, INC. (0001300734) (Issuer)
3 - SHINECO, INC. (0001300734) (Issuer)
3 - SHINECO, INC. (0001300734) (Issuer)
4 - SHINECO, INC. (0001300734) (Issuer)
4 - SHINECO, INC. (0001300734) (Issuer)
3 - SHINECO, INC. (0001300734) (Issuer)
Expanding the Frontiers of Regenerative Medicine BEIJING, April 23, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on April 22, 2025, its subsidiary, Shineco Life Sciences Group Hong Kong Limited ("Shineco Life Sciences"), entered into a Share Purchase Agreement (the "SPA") with Dr. Lim Kah Meng (the "Seller") to acquire 51% of the equity interest in InfiniClone Limited, a company incorporated under the laws of Hong Kong that has been wholly owned held by Dr. Lim ("InfiniClone"). InfiniClone is a biotechnology company focusing on the field of re
The Acquisition is Expected to Create Immediate Synergies with the Company's Existing Medical Device Business BEIJING, March 25, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on March 20, 2025, Shineco Life Science Group Hong Kong Co., Limited ("Shineco Life Science"), a subsidiary of the Company, entered into a Stock Purchase Agreement ("SPA") with Yi Yang (the "Seller"), for 75% of an equity interest in FuWang (HK) International Company Limited ("FuWang Company"). The Seller is the current and only shareholder of FuWang Company, which specializes i
BEIJING, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (("Shineco" or the "Company", NASDAQ:SISI), a producer of innovative diagnostic medical products and related medical devices, announced today that effective at 12:01 a.m., EDT, on November 12, 2024, the Company will effect a one-for-twenty four (1-for-24) reverse stock split of its outstanding common stock (the "Reverse Stock Split"). The Reverse Stock Split is primarily intended to bring the Company into compliance with the minimum average closing share price requirement for maintaining its listing on the Nasdaq Capital Market. The Company's common stock will continue to trade under the symbol "SISI". Upon the effectiveness of the R
NEW YORK, Aug. 9, 2024 /PRNewswire/ -- Future Fintech Group Inc. (NASDAQ: FTFT), (hereinafter referred to as "Future FinTech", "FTFT" or the "Company"), a comprehensive financial and digital technology service provider, today announced that its Board of Directors (the "Board") approved the appointment of Mr. Hu Li as Chief Executive Officer ("CEO"), President and a member of the Board of the Company, effective August 5, 2024. Mr. Li will be fully responsible for the operation and management of the Company, helping it to expand internationally, manage its investment and financi
Beijing, July 15, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company") (NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, today announced the closing of its underwritten public offering of 1,869,160 shares of its common stock at a public offering price of $1.07 per share of common stock, for aggregate gross proceeds of approximately $2 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 280,374 shares of common stock at the public offering price per share, less the underwriting discounts to cover over-
Beijing, July 12, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company") (NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, today announced the pricing of its underwritten public offering of 1,869,160 shares of its common stock at a public offering price of $1.07 per share of common stock, for aggregate gross proceeds of approximately $2 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 280,374 shares of common stock at the public offering price per share, less the underwriting discounts to cover over-
Beijing, July 11, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company") (NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, today announced it has commenced an underwritten public offering of shares of its common stock and pre-funded warrants to purchase its shares of common stock. All of the shares of common stock and pre-funded warrants and the shares of common stock underlying the pre-funded warrants are being offered by the Company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. EF Hu
The Company believes that its Advanced Proprietary Production Technology Provides it with a Competitive Advantage in the Sector BEIJING, July 10, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that its subsidiary, Fuzhou Meida Health Management Co., Ltd. ("Fuzhou Meida"), has entered into Distribution Agreements (the "Agreements") for its water-soluble phospholipid concentrate health food beverage with a projected goal of more than $30 million in sales with six distribution companies, for a term of three years. Mrs. Jennifer Zhan, CEO of Shineco, said, "Th
BEIJING, June 27, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (("Shineco" or the "Company", NASDAQ:SISI), a producer of innovative diagnostic medical products and related medical devices, announced today that on June 5, 2024, the Company received a formal notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The notice indicated that as a result of the closing bid price of the Company's common stock having been at least $1.00 per share for the period of 10 consecutive business days, from May 20, 2024 through June 4, 2024, th
BEIJING, June 24, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on June 20, 2024, the Company entered into a Securities Purchase Agreement (the "SPA") with certain non-U.S. investors (each individually, a "Purchaser," and collectively, the "Purchasers"). Pursuant to the SPA, the Company will issue up to 1,400,000 shares of its common stock (the "Shares") to the Purchasers in a private placement financing transaction (the "Offering") at an offering price of $5.00 per share. The gross proceeds of the Offering are expected to be approximately $7,000,000,